Evidence map›Paper›PMID 35896522›Full record

ReviewCell death discovery2022

Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer.

Liqing Lu, Ye Zhang, Xuemei Tan, Yulia Merkher, Sergey Leonov, Li Zhu, Yalan Deng, Huajun Zhang, Dandan Zhu, Yuying Tan and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in Cell death discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 112 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Dual-pathway induction of pyroptosisActa pharmaceutica Sinica. B · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Liqing Lu *Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
Ye Zhang *Department of Oncology, NHC Key Laboratory of Cancer Proteomics & State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China.
Xuemei TanDepartment of Gastroenterology, Xiangya Hospital, Central South University, Changsha, China.
Yulia MerkherSchool of Biological and Medical Physics, Moscow Institute of Physics and Technology, 141700, Dolgoprudny, Moscow Region, Russia.
Sergey LeonovSchool of Biological and Medical Physics, Moscow Institute of Physics and Technology, 141700, Dolgoprudny, Moscow Region, Russia.
Li ZhuShanghai Institute of Precision Medicine, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 200125, Shanghai, China.
Yalan DengDepartment of Oncology, NHC Key Laboratory of Cancer Proteomics & State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China.
Huajun ZhangDepartment of Oncology, NHC Key Laboratory of Cancer Proteomics & State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China.
Dandan ZhuDepartment of Oncology, NHC Key Laboratory of Cancer Proteomics & State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China.
Yuying TanDepartment of Oncology, NHC Key Laboratory of Cancer Proteomics & State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China.
Ying FuDepartment of Oncology, NHC Key Laboratory of Cancer Proteomics & State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China.
Ting LiuDepartment of Gastroenterology, Xiangya Hospital, Central South University, Changsha, China. liuting818@126.com.ORCID http://orcid.org/0000-0001-8178-6532
Yongheng ChenDepartment of Oncology, NHC Key Laboratory of Cancer Proteomics & State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China. yonghenc@163.com.ORCID http://orcid.org/0000-0001-8139-6892
Central South University · CNMoscow Institute of Physics and Technology · RUShanghai Jiao Tong University · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81570537National Natural Science Foundation of China (National Science Foundation of China) 81902858National Natural Science Foundation of China (National Science Foundation of China) 81974074National Natural Science Foundation of China (National Science Foundation of China) 82070632
6 · The paper itself

Abstract

Pyroptosis, a type of inflammatory programmed cell death, is triggered by caspase cleavage of gasdermin family proteins. Based on accumulating evidence, pyroptosis is closely associated with tumour development, but the molecular mechanism underlying pyroptosis activation and the signalling pathways regulated by pyroptosis remain unclear. In this review, we first briefly introduce the definition, morphological characteristics, and activation pathways of pyroptosis and the effect of pyroptosis on anticancer immunity. Then we review recent progress concerning the complex role of pyroptosis in various tumours. Importantly, we summarise various FDA-approved chemotherapy drugs or natural compounds that exerted antitumor properties by inducing pyroptosis of cancer cells. Moreover, we also focus on the current application of nanotechnology-induced pyroptosis in tumour therapy. In addition, some unsolved problems and potential future research directions are also raised.

Identifiers

PMID35896522
PMCPMC9329358
OpenAlexW4288052404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.